Halozyme Therapeutics – Financials

	売上高	純利益	EPS	Q/Q	margin
2024Q2	231,353	93,245	0.72	5%	40%
2024Q1	195,879	76,823	0.60	21%	39%
2023Q4	230,039	85,388	0.65	27%	37%
2023Q3	216,033	81,837	0.61	3%	38%
2023Q2	221,038	74,754	0.56	45%	34%
2023Q1	162,143	39,615	0.29	38%	24%
2022Q4	181,496	57,702	0.41	78%	32%
2022Q3	208,976	61,634	0.44	80%	29%
2022Q2	152,365	22,685	0.16	12%	15%
2022Q1	117,279	60,108	0.43	32%	51%
2021Q4	102,003	66,770	0.45	-16%	65%
2021Q3	115,830	216,587	1.48	77%	187%
2021Q2	136,455	91,458	0.62	147%	67%
2021Q1	89,022	27,895	0.19	251%	31%
2020Q4	121,703	73,164	0.51	127%	60%
2020Q3	65,316	36,207	0.25	41%	55%
2020Q2	55,221	25,817	0.19	41%	47%
2020Q1	25,354	-6,103	-0.04	-55%	-24%
2019Q4	53,665	-34,397	-0.24	-11%	-64%
2019Q3	46,230	-25,015	-0.17	81%	-54%
2019Q2	39,148	-14,624	-0.1	11%	-37%
2019Q1	56,949	1,796	0.01	84%	3%
2018Q4	60,232	-2,126	-0.01	-68%	-4%
2018Q3	25,556	-27,850	-0.19	-60%	-109%
2018Q2	35,202	-22,893	-0.16	4%	-65%
2018Q1	30,872	-27,461	-0.19	4%	-89%
2017Q4	189,564	123,882	0.85	386%	65%
2017Q3	63,731	2,749	0.02	100%	4%
2017Q2	33,750	-30,763	-0.26	1%	-91%
2017Q1	29,568	-32,897	-0.26	-30%	-111%
2016Q4	39,003	-27,386	-0.21	-25%	-70%
2016Q3	31,853	-28,946	-0.23	53%	-91%
2016Q2	33,336	-26,875	-0.21	-23%	-81%
2016Q1	42,449	-19,816	-0.16	127%	-47%
2015Q4	52,227	4,318	0.03	72%	8%
2015Q3	20,780	-24,460	-0.19	42%	-118%
2015Q2	43,384	3,019	0.02	136%	7%
2015Q1	18,666	-15,108	-0.12	56%	-81%
2014Q4	30,377	-5,274	-0.04		-17%
2014Q3	14,606	-20,280	-0.16		-139%
2014Q2	18,385	-16,273	-0.13		-89%
2014Q1	11,966	-26,548	-0.22		-222%

　　　　　　　　　　　　　　　　　　　　　　　　　　(In thousands dollars)